A kind of dpp-4 inhibitor with piperazine structure

A technology of isomers and compounds, applied in the field of organic synthesis, can solve the problems of limited varieties of diabetes and inability to meet clinical needs, etc.

CN103910734BActive Publication Date: 2016-01-13NANJING HUAWE MEDICINE TECH DEV
8 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Publication Date
2016-01-13

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a novel dipeptidyl peptidase IV (DPP-4) inhibitor namely a chemical compound shown in formula (I) with a piperazine structure. The chemical compound, and optical isomers and pharmaceutically acceptable salts of the chemical compound can be used for treating diabetes mellitus, especially non-insulin dependent diabetes mellitus and other diseases relative to DPP-4, wherein the definition of the substituent group X in the general formula (I) is the same as that in the specification.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of organic synthesis, and specifically relates to a dipeptidyl peptidase IV (hereinafter referred to as DPP-4) inhibitor compound with a piperazine structure and its application for treating and preventing diabetes and other diseases related to DPP-4. Background technique

[0002] Diabetes is a chronic metabolic disease caused by various pathogenic factors such as genetic factors, immune dysfunction, microbial infection and its toxins, free radical toxins, and mental factors. Clinically, it is characterized by hyperglycemia. Can be divided into type 1 diabetes (insulin-dependent), type 2 diabetes (non-insulin-dependent), gestational diabetes and other special types of diabetes. Type 2 diabetes accounts for about 95% of diabetic patients.

[0003] At present, the main oral hypoglycemic agents are: sulfonylureas (SU), biguanides, α-glucosidase inhibitors, non-sulfonylurea insulin secretory drugs and insulin sensitizers...

Examples

Embodiment 1

[0059] Chemical reaction formula:

[0060]

[0061] first step reaction

[0062] Weigh 6.63g of 2-aminopyrazine and 16.78g of ethyl 2-bromotrifluoromethyl acetate and mix them into a 250mL round bottom flask, measure 50mL of ethanol to dissolve and stir evenly, heat and stir at 95°C overnight. TLC detection (EA: MeOH = 20: 1, ammonia water) reaction process, after the raw materials are almost completely reacted, the sample is directly mixed and passed through the column to collect the product point (PE: EA = 20: 1 ~ 1: 1), concentrated to obtain intermediate 1 about 5.5 g, as light yellow solid, the yield is about 30%.

[0063] second step reaction

[0064] Measure about 100mL of MeOH to dissolve 5.5g of intermediate 1, add 1.1g of palladium carbon catalyst, replace with nitrogen three times and then replace with hydrogen three times, heat and stir at 30°C overnight, and seal under normal pressure for hydrogen protection. TLC detection (EA: MeOH = 20: 1, ammonia water) r...

Embodiment 2

[0073] The preparation of embodiment 2 compound 1-2

[0074] Chemical reaction formula:

[0075]

[0076] Dissolve 0.2g of intermediate 4 in 10ml of toluene, then add triphenylphosphine (1.5ep), dropwise add DEAD (1.5ep) under ice-water bath conditions, finally add 2.0ep methanol to the reaction solution, and then Stirring and reacting for 24 hours, TLC detection showed that the reaction of the raw materials was complete, and concentrated under reduced pressure. The obtained product was deprotected by methanol / concentrated hydrochloric acid to obtain about 100 mg of the target product I-2.

[0077] MS: 465[M+H],

[0078] H-NMR: δ7.44-7.35(m, 1H), 7.29-7.26(m, 1H), 5.19-5.06(m, 2H), 4.34-4.30(m, 1H), 4.12-4.02(m, 2H) , 3.94-3.84 (m, 5H), 3.20-2.89 (m, 2H), 2.83-2.81 (m, 2H).

Embodiment 3

[0079] The preparation of embodiment 3 compound I-7

[0080] Chemical reaction formula:

[0081]

[0082] Add 0.50 g of intermediate 4, 10 mL of DMF, 2.0 ep of triethylamine, 1.3 ep of HOBT and 1.5 ep of EDC·HCl into a 100 ml three-necked flask, stir at room temperature for 1 h, add 1.0 ep of methylamine in tetrahydrofuran, and react overnight at 31 ° C. TLC (DCM: MeOH=20:1, 2 drops of ammonia) tracked the completion of the reaction, the reaction solution was poured into 200ml of ice water, a large amount of white solid was precipitated, suction filtered, the filter cake was washed with water, and dried in vacuo at 45°C to obtain 0.55g of a gray solid. The obtained product was de-boc-protected to obtain compound I-7.

[0083] MS: 464[M+H],

[0084] H-NMR: δ7.43-7.35(m, 1H), 7.26-7.24(m, 1H), 5.18-5.06(m, 2H), 4.36-4.31(m, 1H), 4.16-4.02(m, 2H) , 3.97-3.92 (m, 2H), 3.24-2.87 (m, 2H), 2.87-2.82 (m, 2H), 2.75 (s, 3H).

[0085] Compound I-3, Compound I-4, and Compound I-5 wer...